Loading data for OCUL — first visit, this takes a few seconds.
Ocular Therapeutix Inc. (OCUL)
NasdaqGM: OCUL
· Real-Time Price · USD
11.73
+0.72 (6.54%)
At close: Aug 27, 2026, 3:28 PM
The price, the headline numbers and the latest news, in one place.
Ocular Therapeutix Inc. (OCUL) Stock Price, Analysis & Data
6.54% (1D)
No data available
| Bid | 6.26 |
| Market Cap | 2.39B |
| Revenue (ttm) | 52.05M |
| Net Income (ttm) | -301.45M |
| 0.94 | |
| -1.4 | |
| n/a | |
| -7.49 | |
| P/B (ttm) | 4.60 |
| P/S (ttm) | 45.92 |
| Earnings Date | n/a |
| Ask | 10.89 |
| Volume | 2,965,797 |
| Avg. Volume (20D) | 2,701,922 |
| Open | 11.29 |
| Previous Close | 11.01 |
| Day's Range | 11.19 - 11.74 |
| 52-Week Range | 6.23 - 16.44 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About OCUL
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing...
Industry Biotechnology
Sector Healthcare
IPO Date Jul 25, 2014
Employees 325
Stock Exchange NasdaqGM
Ticker Symbol OCUL
Website https://www.ocutx.com
Financial Performance
In 2025, Ocular Therapeutix's revenue was 51.95M, a decrease of -18.47% compared to the previous year's 63.72M. Earnings were -265.94M, an increase of 37.43%.
Financial Statements
Page 1 of 2